Changes in Hong Kong stocks | Zhaoyan Pharmaceutical (06127) rose more than 4%. New orders in the first half of the year nearly doubled, and production capacity construction at the company's two major bases continues to advance

The Zhitong Finance App learned that Zhaoyan New Pharmaceutical (06127) rose by more than 4%. As of press release, it had risen 4.15% to HK$27.62, with a turnover of HK$181 million.

According to the news, Zhaoyan Pharmaceutical previously disclosed its interim results. In the first half of 2026, the company's overall order amount was about RMB 3.7 billion, up 60.9% year on year; the amount of new orders signed was about RMB 2.02 billion, up 98.0% year on year, of which 2026Q2 new orders amounted to RMB 1.11 billion, up 88.14% year on year and 21.98% month on month. Western Securities pointed out that the company's production capacity construction continues to advance. Among them, the 2026H1 and Beijing experimental facilities have been expanded by 5,000 square meters, and this expansion will further enhance the company's overall business carrying capacity and operating throughput; the 2026H1 Guangzhou base project successfully passed the joint inspection of government departments, and various departments were organized to complete internal inspection and confirmation of each specialty of the project.

CITIC Construction Investment said that in the first half of the year, the company's new orders achieved a sharp rise in volume and price, with price changes contributing even more. The gross margin for projects corresponding to new orders in the current period has rebounded to the 30% to 35% range. The bank believes that the increase in contract signing for innovative drug projects is expected to optimize the order structure and enhance revenue visibility; as new 26H1 orders are gradually transferred to 2027-2028 revenue and profit, the company's revenue growth rate and gross margin level are expected to increase significantly in the next two years, and abundant on-hand orders at the end of the period will also support subsequent revenue growth and laboratory service profit recovery.